Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02884544 · ClinicalTrials.gov registry record · Phase 2
A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD
A Phase 2 study, sponsored by Ironshore Pharmaceuticals and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02884544 is a Phase 2 study that has completed, run by Ironshore Pharmaceuticals and Development. The registered enrollment target is 22 participants.
The verdict
NCT02884544, a Phase 2 study, has completed, sponsored by Ironshore Pharmaceuticals and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The phase 2 study will evaluate the safety, tolerability and efficacy of HLD100 at steady state (following up to 5 weeks of treatment) in children using an outpatient, single-center, open-label, flexible dose-escalation study design.
Interventions
- DRUG HLD100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-08 |
| Est. Completion | 2016-12-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02884544
The ClinicalTrials.gov registry entry for NCT02884544 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ironshore Pharmaceuticals and Development, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HLD100 is the first listed.
NCT02884544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02884544 about?
NCT02884544 is a clinical study titled "A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD". The phase 2 study will evaluate the safety, tolerability and efficacy of HLD100 at steady state (following up to 5 weeks of treatment) in children using an outpatient, single-center, open-label, flexible dose-escalation study design.
What is the current status of trial NCT02884544?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2016-08. Estimated completion is 2016-12-27.
What interventions are being tested in trial NCT02884544?
The interventions under investigation include: HLD100 (DRUG).
Who is sponsoring clinical trial NCT02884544?
This trial is sponsored by Ironshore Pharmaceuticals and Development, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.